Fast whole-brain three-dimensional macromolecular proton fraction mapping in multiple sclerosis von Yarnykh, Vasily L, Bowen, James D, Samsonov, Alexey, Repovic, Pavle, Mayadev, Angeli, Qian, Peiqing, Gangadharan, Beena, Keogh, Bart P, Maravilla, Kenneth R, Jung Henson, Lily K

Volltext

Quality of life in individuals newly diagnosed with multiple sclerosis or clinically isolated syndrome von Alschuler, Kevin N., Whibley, Daniel, Kratz, Anna L., Jensen, Mark P., Wundes, Annette, von Geldern, Gloria, Qian, Peiqing, Bombardier, Charles H., Ehde, Dawn M.

Volltext

Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis von Alvarez, Enrique, Steinman, Lawrence, Fox, Edward J, Hartung, Hans-Peter, Qian, Peiqing, Wray, Sibyl, Robertson, Derrick, Selmaj, Krzysztof, Wynn, Daniel, Mok, Koby, Xu, Yihuan, Bodhinathan, Karthik, Miskin, Hari P, Cree, Bruce A C

Volltext

Spinal cord tract diffusion tensor imaging reveals disability substrate in demyelinating disease von Naismith, Robert T, Xu, Junqian, Klawiter, Eric C, Lancia, Samantha, Tutlam, Nhial T, Wagner, Joanne M, Qian, Peiqing, Trinkaus, Kathryn, Song, Sheng-Kwei, Cross, Anne H

Volltext

Research on hydrological survey and forecasting model based on rolling sampling Markov chain von Yi, Wei, Qian, Peiqing

Volltext

Recurrent primary biliary cirrhosis: Peritransplant factors and ursodeoxycholic acid treatment post‐liver transplant von Guy, Jennifer E., Qian, Peiqing, Lowell, Jeffrey A., Peters, Marion G.

Volltext

Hepatitis resulting from liver-specific expression and recognition of self-antigen von Buxbaum, James, Qian, Peiqing, Allen, Paul M, Peters, Marion G

Volltext

Earlier Initiation of Ublituximab Treatment Is Associated with Improved Disability Outcomes Among Treatment Naïve Participants in ULTIMATE I and II (P9-6.001) von Robertson, Derrick, Hartung, Hans-Peter, Qian, Peiqing, Wray, Sibyl, Lee, Lily, Mok, Koby, Garner, Christopher, Alvarez, Enrique

Volltext

Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis von Steinman, Lawrence, Fox, Edward, Hartung, Hans-Peter, Alvarez, Enrique, Qian, Peiqing, Wray, Sibyl, Robertson, Derrick, Huang, DeRen, Selmaj, Krzysztof, Wynn, Daniel, Cutter, Gary, Mok, Koby, Hsu, Yanzhi, Xu, Yihuan, Weiss, Michael S., Bosco, Jenna A., Power, Sean A., Lee, Lily, Miskin, Hari P., Cree, Bruce A.C.

Volltext

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial von Cadavid, Diego, Mellion, Michelle, Hupperts, Raymond, Edwards, Keith R, Calabresi, Peter A, Drulović, Jelena, Giovannoni, Gavin, Hartung, Hans-Peter, Arnold, Douglas L, Fisher, Elizabeth, Rudick, Richard, Mi, Sha, Chai, Yi, Li, Jie, Zhang, Yiwei, Cheng, Wenting, Xu, Lei, Zhu, Bing, Green, Susan M, Chang, Ih, Deykin, Aaron, Sheikh, Sarah I, Agüera Morales, Eduardo, Al Khedr, Abdullatif, Ampapa, Radek, Arroyo, Rafael, Belkin, Martin, Bonek, Robert, Boyko, Alexey, Capra, Ruggero, Centonze, Diego, Clavelou, Pierre, Debouverie, Marc, Drulovic, Jelena, Edwards, Keith, Evangelou, Nikos, Evdoshenko, Evgeniy, Fernández, Oscar, Fernández Sánchez, Victoria, Freedman, Mark, Freedman, Steven, Fryze, Waldemar, Garcia-Merino, Antonio, Gavric-Kezic, Mira, Ghezzi, Angel, Gout, Olivier, Grimaldi, Luigi, Hertmanowska, Hanka, Hintzen, Rogier, Hradilek, Pavel, Hupperts, Raymond, Ilkowski, Jan, Ivashinenkova, Evelina, Izquierdo, Guillermo, Jacques, Francois, Jakab, Gabor, Khabirov, Farit, Klodowska-Duda, Gabriela, Komoly, Samuel, Kostic, Smiljana, Kovarova, Ivana, Kremenchuzky, Marcelo, Laganke, Christopher, LaPierre, Yves, Maciejowski, Maciej, Maison, Francois Grand, Marfia, Girolama Alessandra, Martínez Yélamos, Sergio, Meluzinova, Eva, Montalban, Xavier, Murray, Ronald, Naismith, Robert, Newsome, Scott, Nguyen, Viet, Oreja, Delia, Pardo, Gabriel, Pasechnik, Elena, Patti, Francesco, Potemkowski, Andrzej, Prokopenko, Semen, Qian, Peiqing, Rodríguez-Antigüedad, Alfredo, Rossman, Howard, Rozsa, Csilla, Sánchez López, Fernando, Selmaj, Krzysztof, Silber, Eli, Stepien, Adam, Stepniewska, Anna, Swiat, Maciej, Toncev, Gordana, Tourbah, Ayman, Trushnikova, Tatyana, Uccelli, Antonio, Vachova, Marta, Valis, Martin, Vecsei, Laszlo, Wiertlewski, Sandrine, Zaffaroni, Mauro, Zielinski, Tomasz

Volltext

Disease Outcomes With Ublituximab in Participants With Highly Active Disease: Subpopulation Analyses of the Phase 3 ULTIMATE I and II Studies in Participants With Relapsing Multipl... von Alvarez, Enrique, Steinman, Lawrence, Hartung, Hans-Peter, Fox, Edward, Qian, Peiqing, Wray, Sibyl, Robertson, Derrick, Mok, Koby, Garner, Christopher A., Cree, Bruce

Volltext

Long term efficacy and safety of Dimethyl Fumarate: A 3 year follow-up in a single MS center (P6.335) von Qian, Peiqing, Joo, Julia, Scanlan, James, Bowen, James

Volltext

Ublituximab Efficacy in Treatment-Naive Participants With Relapsing Multiple Sclerosis in the Phase 3 ULTIMATE I and II Studies (P6-3.015) von Steinman, Lawrence, Fox, Edward, Hartung, Hans-Peter, Alvarez, Enrique, Qian, Peiqing, Wray, Sibyl, Robertson, Derrick, Huang, Deren, Selmaj, Krzysztof, Wynn, Daniel, Bosco, Jenna, Mok, Koby, Garner, Christopher A., Cree, Bruce

Volltext

Oral rather than intravenous corticosteroids should be used to treat MS relapses – No von Bowen, James D, Qian, Peiqing

Volltext

Disability Improvements With Ublituximab in Relapsing Multiple Sclerosis (RMS): Expanded Disability Status Scale (EDSS), 9-Hole Peg Test (9-HPT), and Timed 25-Foot Walk (T25FW) Eva... von Cree, Bruce, Fox, Edward, Hartung, Hans-Peter, Alvarez, Enrique, Qian, Peiqing, Wray, Sibyl, Robertson, Derrick, Huang, DeRen, Selmaj, Krzysztof, Wynn, Daniel, Weiss, Michael S., Bosco, Jenna A., Power, Sean A., Mok, Koby, Lee, Lily, Steinman, Lawrence

Volltext

Infusion-Related Reactions (IRRs) With Ublituximab in Patients With Relapsing Multiple Sclerosis (RMS): Post Hoc Analyses From the Phase 3 ULTIMATE I and II Studies (P6-4.010) von Fox, Edward, Steinman, Lawrence, Hartung, Hans-Peter, Alvarez, Enrique, Qian, Peiqing, Wray, Sibyl, Robertson, Derrick, Huang, DeRen, Selmaj, Krzysztof, Wynn, Daniel, Weiss, Michael S., Bosco, Jenna A., Power, Sean A., Mok, Koby, Lee, Lily, Cree, Bruce

Volltext

Relapse Rate and Time to First Relapse Were Improved With Ublituximab vs Teriflunomide in the Phase 3 ULTIMATE I and ULTIMATE II Studies in Patients With Relapsing Multiple Scleros... von Steinman, Lawrence, Fox, Edward, Hartung, Hans-Peter, Alvarez, Enrique, Qian, Peiqing, Wray, Sibyl, Robertson, Derrick, Huang, DeRen, Selmaj, Krzysztof, Wynn, Daniel, Weiss, Michael S., Bosco, Jenna A., Power, Sean A., Mok, Koby, Lee, Lily, Cree, Bruce

Volltext

Ublituximab Treatment Is Associated With a Significant Proportion of Patients Achieving No Evidence of Disease Activity (NEDA): Results From the Ultimate I and Ultimate II Phase 3... von Alvarez, Enrique, Steinman, Lawrence, Fox, Edward, Hartung, Hans-Peter, Qian, Peiqing, Wray, Sibyl, Robertson, Derrick, Huang, DeRen, Selmaj, Krzysztof, Wynn, Daniel, Weiss, Michael S., Bosco, Jenna A., Power, Sean A., Mok, Koby, Lee, Lily, Cree, Bruce

Volltext

Temporal Trends in Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccines Among Multiple Sclerosis Patients Treated With Natalizumab, Ocrelizumab or Fumarates (P14-4.006... von Repovic, Pavle, Choi, Jongchan, Hong, Sunga, Reola, Jennifer, Chun, Kelly, Petropoulos, Christos, Bowen, James, Qian, Peiqing, Evans, Simon, Edmark, Rick, Mendoza, Jason, Avila-Carey, Robin, Heath, James, Goldman, Jason

Volltext

Saccadic Intrusions Are Rare In Multiple Sclerosis (P2.167) von DePledge, Lisa, Repovic, Pavle, Bowen, James, Qian, Peiqing, Severson, Bobbie, Hamilton, Steven, Keung, Bonnie, May, Eugene

Volltext